DMD #27037

Introduction
Enterohepatic cycling (EHC) is a distributional event in which a compound is absorbed from the intestine, excreted into bile and then reabsorbed into the portal vein following bile secretion into the intestine (Rowland and Tozer, 1995) . This type of recirculation may occur to the administered compound directly and/or indirectly via its metabolite(s). For metabolite-mediated indirect EHC of a compound, one of the most common pathways is via a glucuronide conjugate (Scheline, 1973; Dickinson et al., 1979; Horton and Pollack, 1991; Bullingham et al., 1996; Skonberg et al., 2008) . In these instances, the dosed compound (aglycone) experiences enzyme-mediated glucuronidation and the resulting glucuronide undergoes biliary clearance, ultimately entering the intestine upon bile secretion. Once in the intestinal lumen, the glucuronide is hydrolyzed, typically enzymatically (Scheline, 1973; Parkinson, 2001) , to the aglycone, which reenters portal circulation. This process often results in a "double-humped" plasma concentration-time curve following oral dosing (Dickinson et al., 1979; Bullingham et al., 1996; Wajima et al., 2002) , with the second peak arising from the originally ingested compound entering systemic circulation following its EHC causing increased exposure and a prolonged half-life.
Herein we report the absorption, metabolism and excretion of (1S,5R)-2,3,4,5-tetrahydro-7-(trifluoromethyl)-1,5-methano-1H-3-benzazepine (1), an α 4 β 2 nicotinic acetylcholine receptor partial agonist (Coe et al., 2005) potentially useful for smoking cessation, in Sprague-Dawley rats following a single oral dose of [ 14 C]1 (Figure 1 ).
During this radiolabeled mass balance study, specific phenomena were observed that suggested the enterohepatic recirculation of 1 via an N-carbamoyl glucuronide, its major DMD #27037 5 metabolite. To investigate this particular disposition further, a subsequent intravenous bolus study was conducted with 1 in both intact and BDC rats. A combination of the results from both the radiolabeled oral study and the non-radiolabeled intravenous pharmacokinetics study provided an integrated data set to define mechanistically the indirect EHC of 1 via its N-carbamoyl glucuronide in Sprague-Dawley rats.
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All blood samples were collected into anticoagulant-free tubes and processed immediately to obtain serum. Control serum was harvested from blood collected from untreated animals that were not sacrificed.
Determination of Radioactivity within Biological Matrices. Triplicate gravimetric aliquots of each sample of urine (0.1 g), bile (0.05-0.1 g) and serum (0.05-0.1 g) were mixed with liquid scintillation cocktail (10 mL for bile, 5 mL for all other matrices) and counted for 2 min in a Model LS 6000 or LS 6500 liquid scintillation counter (Beckman Instruments, Richmond, CA).
Fecal samples were homogenized with deionized H 2 O (20% w/w, feces/H 2 O) using a probe-type homogenizer. Cage debris/rinse samples (collected in 50% reagent alcohol in H 2 O) were homogenized directly with a probe-type homogenizer. Triplicate gravimetric aliquots (0.1-0.5 g for either fecal homogenate or cage debris/rinse homogenate) were transferred into tared cones and pads, weighed and combusted prior to radioanalysis.
Sample combustion was performed using a Model 307 or 387 Sample Oxidizer (PerkinElmer Life Sciences, Inc., Boston, MA). Combustion efficiency using a [ 14 C]standard was determined daily prior to the combustion of study samples, and the measured radioactivity content in feces and cage debris/rinse was adjusted using daily combustion efficiency values. Liberated [ 14 C]CO 2 was trapped in Carbo-Sorb ® E (Packard Instruments, Meriden, CT) and mixed with Permafluor E+ scintillation fluid (PerkinElmer Life Sciences, Inc.), and the samples were analyzed for total radioactivity in a Model LS 6000 or LS 6500 liquid scintillation counter (Beckman Coulter, Inc., Fullerton, CA) for 2 min. Scintillation counter data were automatically corrected for DMD #27037 9 counting efficiency using an external standardization technique and an instrument-stored quench curve generated from a series of sealed quench standards.
Thawed brains were weighed, diluted with H 2 O (3 mL H 2 O/g brain) and
homogenized with a probe-type homogenizer. Following liquefaction, aliquots (0.2 g) of brain homogenate in scintillation cocktail (7 mL) were analyzed by LSC for 5 min.
Quantitative Analysis of 1 in Serum from Radiolabeled Studies. Serum concentrations of 1 were quantified using a characterized LC-MS/MS assay. To ensure that serum concentrations of 1 were within the dynamic range of the analytical assay, all samples, except the pre-dose samples, were diluted accordingly prior to analysis. To each serum aliquot (100 μL) contained in a 15 mL glass centrifuge tube was added 20%
MeCN in H 2 O (10 μL) containing an internal standard. Each sample was basified (100 μL, 0.1 M NaOH) and extracted with methyl tert-butyl ether (4 mL) via vortex-mixing and centrifugation (1,811 rcf for 10 min). The organic supernatant was transferred to a clean 15 mL glass centrifuge tube, concentrated to dryness under N 2 at 35 °C, and reconstituted in 20% MeCN in 10 mM ammonium formate, pH 3.0 (250 μL, Solvent A). determine the pharmacokinetic parameters of total radioactivity were calculated by converting the raw data generated by LSC to concentrations (ng-eq./mL) using the specific activity (3.6 mCi/mmol) of administered [ 14 C]1. The AUC 0-24 was calculated using the linear trapezoidal method, k el was determined by linear regression of the log concentration versus time data during the last observable elimination phase, half-life (t 1/2 ) was calculated as 0.693/k el and AUC 0-∞ was calculated as the sum of AUC 0-24 and AUC 24-∞ , which was determined by dividing the plasma concentration at 24 h post-dose by k el . Both maximal serum concentration (C max ) and its first time of occurrence (T max ) were taken directly from the serum concentration versus time data. Means and standard deviations were calculated when half or greater of the values exceeded the LLOQ for 1 (0.25 ng/mL) or total radioactivity (2× background radioactivity, which equated to 48 ngeq./mL). A value of 0 was used when a measured value was <LLOQ.
Sample Preparation for Metabolite Profiling and Identification. At each step during the sample preparation of all biological matrices, total radioactivity levels were determined by LSC for recovery calculations. Following preparation, all samples were This article has not been copyedited and formatted. The final version may differ from this version. Urine. Urine samples from each rat collected from 0-72 h post-dose representing ≥93% of total urinary radioactivity were pooled proportional to the amount of urine in each sampling period. Pooled samples were centrifuged (1,811 rcf for 5 min) to remove particulate materials, and the resulting supernatants were analyzed directly.
Bile. Bile collected from 0-24 h post-dose representing >89% of total biliary radioactivity were pooled proportional to the amount of bile in each sampling period.
Pooled samples were centrifuged (1,811 rcf for 5 min) to sediment particulate materials affording the analytical supernatant.
Feces. Fecal homogenates (ca. 1.0 to 7.7 g) from each rat collected from 0-96 h postdose, representing ≥95% of total fecal radioactivity, were pooled proportional to the amount of feces in each sampling period. After mixing at 37 °C for 14 h in a reciprocal water bath, pooled fecal homogenates were diluted with MeCN (3 mL/g homogenate),
vortex-mixed and centrifuged (1,811 rcf for 10 min), and the resulting supernatants were isolated. If necessary, the remaining fecal pellets were extracted further with 33% H 2 O in MeCN (6 mL) until ≥90% of the radioactivity, as determined by LSC analysis of the combined supernatants, from each pooled sample was extracted. The supernatants were concentrated to dryness by a N 2 stream at 35 °C and reconstituted in 10% MeCN in 10 mM ammonium formate, pH 3.4 (1 mL) for analysis.
Serum. Serum from blood samples collected by terminal bleeding of rats at 1, 4, 8
and 24 h post-dose were used for circulatory metabolite profiling and identification.
Serum samples were pooled within gender according to the method of Hamilton et al. (Hamilton et al., 1981) ; i.e. 1.0, 1.8, 5.0 and 4.0 mL, respectively, of serum from each time point sample were combined to afford 11.8 mL of pooled serum for each gender profile. Proteins were precipitated from the serum pools by the addition of MeCN (24 mL), and the samples were vortex-mixed and centrifuged (1,811 rcf for 10 min). The remaining serum protein pellets were extracted an additional time with MeCN (4 mL) to ensure that >90% of radioactivity, as determined by LSC analysis of the pooled supernatants, from each pooled serum sample was extracted. The combined supernatants were concentrated to dryness and the resulting residues were reconstituted in 10 mM ammonium formate, pH 3.4 (0.6 mL) and analyzed by LC-MS/MS. Quantitative analysis was achieved by isolating HPLC effluent by a fraction collector set at 30 s intervals, and each respective fraction was mixed with TruCount scintillation fluid (7 mL) and subjected to LSC for 5 min. Individual serum radiochromatograms were generated from respective liquid scintillation data using by an LC-MS/MS (described previously) equipped with an Agilent Zorbax SB-C18
analytical column (5 μ, 4.6 × 150 mm) in series with a β-RAM radiometric detector (IN/US Systems, Inc., Tampa, FL) containing a liquid scintillant cell (500 μL). Analytes within sample aliquots (25-100 μL) were eluted at 1 mL/min with 10 mM ammonium formate, pH 3.4 (Solvent C) and MeCN (Solvent B). The following gradient was employed: 0-20 min, 10% Solvent B in Solvent C; 20-55 min, 10%-50% B in C; 55-58 min, 50%-80% B in C; 58-60 min, 80% C in B. Following the elution of 1 and its metabolites, the column was returned over 1 min to 10% B in C where it remained for 4 min prior to the next injection. Due to the coelution of two biliary metabolites (i.e. M5
and M6) using the aforementioned gradient, bile samples were injected a second time using the same gradient profile but substituting 10 mM ammonium acetate, pH 7.0 as Solvent C to achieve baseline resolution of M5 and M6. For each matrix, >99% of the radioactivity injected onto the column eluted during the 65 min gradient programs.
HPLC effluent was split 1:9 between the mass spectrometer and the radiometric flow detector; liquid scintillation cocktail flowed at 3 mL/min to the radiometric detector.
This article has not been copyedited and formatted. The final version may differ from this version. Sheffield, UK) software were used for the acquisition and processing of mass spectral and radiochromatographic data, respectively. Metabolites were quantified by peak integration within generated radiochromatograms.
In Vitro Generation of N-Carbamoyl Glucuronide M6 (Schaefer, 1992) .
Incubations (2.5 mL) were performed in a capped, but vented 15 mL Erlenmeyer flask under a CO 2 -saturated atmosphere at 37 °C in a shaking water bath. Each incubation contained male RLMs (2 mg of protein/mL 0.1 M NaHCO 3 buffer, pH 7. interval, transferred to a 1.2 mL polypropylene tube, and stored at -20 °C until analysis.
Bile was collected via the bile duct catheter over the same time intervals as urine collection, and stored as described for urine samples.
Quantitative Analysis of 1 in Serum, Urine and Bile from Non-radiolabeled Studies. Serum, urine and bile concentrations of 1 were quantified using the characterized LC-MS/MS assay formerly described with a dynamic range of 0.25 to 50.0 ng/mL for 1. To ensure that serum concentrations of 1 were within the dynamic range of the analytical assay, all samples, except the pre-dose samples, were diluted accordingly prior to analysis. Serum work-up was the same as discussed previously. For urine and bile, to each sample aliquot (100 μL) contained in a 15 mL glass centrifuge tube was added both 20% MeCN in H 2 O (10 μL) containing an internal standard and MeCN (2 mL). The diluted sample was vortex-mixed and centrifuged (600 rcf for 10 min). The organic supernatant (2 mL) was transferred to a clean 15 mL glass centrifuge tube, concentrated to dryness under N 2 at 35 °C, and reconstituted in 20% MeCN in Solvent A (200 μL). Sample analysis was identical to that already described.
Pharmacokinetic Calculations for Non-radiolabeled Studies. For intravenous studies with 1, the estimated initial concentration (C 0(est) ), area under the serum concentration-time curve from time 0 to the last measurable serum concentration (AUC 0-Tlast ), AUC 0-∞ , k el , t 1/2 , total serum clearance (CL) and volume of distribution at steadystate (V ss ) were calculated from the serum concentration versus time data in individual animals by noncompartmental analysis as described beforehand. The cumulative percent of the dose recirculated was calculated as follows (Horton and Pollack, 1991) , where Renal clearance (CL R ) or biliary clearance (CL bil ) of 1 was calculated from the total amount of excreted 1 (A e ) detected within urine or bile, respectively, over 72 h and the serum AUC 0-∞ of the intravenously dosed animals:
This article has not been copyedited and formatted. The final version may differ from this version. Figure 2 , and its gender-specific pharmacokinetic parameters (mean ± SD) are listed in Table 2 . On average in males and females, serum concentrations of 1 rose to a mean C max of 416±74 ng/mL at a mean T max of 5.0±2.4 h post-dose with a mean t 1/2 of 16.2±5.5 h.
For total radioactivity, its average serum concentration-time curve and pharmacokinetic parameters (mean ± SD) are also in Figure 2 and On average in males and females, the mean C max and T max values of total radioactivity were 733±85 ng-eq./mL and 7.0±3.0 h, respectively, while the mean t 1/2 was 51.1±38.3 h.
It is important to note that the reported elimination half-lives for both 1 and total radioactivity are considered estimates since the span ratio was less than two, and this has direct consequences on the degree of confidence in presented CL/F and AUC values, which also are estimates at best. On average in both genders, the AUC 0-∞ for 1 represented 25.3% of the AUC 0-∞ for total drug-related material. Interestingly, serum concentration-time curves for both 1 and total 14 C had a double-humped profile with the second upward leg occurring at ca. 6 h post-dose, suggestive of the EHC of 1. , 199, 196, 191, 179, 177, 159 and 141 (Table 3) ; structures for the majority of these fragment ions were mechanistically rationalized to facilitate metabolite structure elucidation (Figure 3 (Huizing and Beckett, 1980; Lindeke, 1982) , to M7, which was the only one of these two compounds detected in vivo. Based on the enzymatic hydrolysis of M5 to a compound with m/z 244 (Miller et al., 2004) , the fact that no carbon-hydroxylated metabolite of 1 was observed in any biological matrix, and the structural rationalization of each fragment ion observed in its CID product ion spectrum (especially the m/z 244 and 226 fragments, which are believed to correspond to
Structural
N-hydroxyl-1 and its dehydrated iminium, respectively), M5 was tentatively identified as
This article has not been copyedited and formatted. The final version may differ from this version. and M3. On average in urine, 55.2%±6.8% of the administered dose was unchanged 1, which equated to a renal clearance of 3× GFR (Davies and Morris, 1993) .
Feces. In addition to 1, only the urinary amino acid metabolites (M1, M2, M3 and M4) were also observed in male feces, with all but M1 detected in female feces. On average in feces, 5.5%±2.1% of the administered dose was unchanged 1 (Table 1) .
Bile. In both genders, two glucuronide metabolites (M5 and M6) were detected in bile with M6 corresponding on average to 68% of administered 1 (Table 1) specific and mean (male and female) pharmacokinetic parameters (mean ± SD) for this study are summarized in Table 5 . No gender differences in intravenous pharmacokinetics were obvious in either intact or BDC rats, thus mean serum concentration-time curves are plotted ( Figure 4 ) and combined datasets were used for the statistical analysis of pharmacokinetic parameters (Table 5) .
When compared to the pharmacokinetics in intact rats, CL in BDC rats was higher (1.7×; t-test p-value <0.01) and V ss lower (1.6×; t-test p-value <0.01) resulting in a correspondingly shorter (2.5×; t-test p-value <0.01) t 1/2 . These results suggest that the disposition of 1 in rats involves EHC. The cumulative percentage of the intravenous dose of 1 undergoing recirculation in rats was calculated to be 56% based on mean AUC 0-∞ in intact and BDC animals. The CL R of 1 in BDC rats was similar to that determined in intact animals, with the changes in CL resulting from higher (2.4×; t-test p-value <0.01) non-renal CL (CL nr ). In BDC rats CL bil accounted for only 0.52% of the CL of 1.
Therefore, biliary excretion of hepatic biotransformation product(s) of 1 and their backconversion to 1 and its reabsorption in the intestine (rather than direct recycling of 1 via biliary secretion) is likely to be the predominant underlying mechanism of EHC of 1 in Sprague-Dawley rats. Due to the lack of a synthetic standard of M6, only qualitative analyses of bile collected from intravenous studies could be conducted to determine the presence of M6 within these samples. Thus, aliquots (100 μL) from bile samples (0-10 h and 10-24 h collection interval samples) underwent the developed metabolite identification LC-MS/MS methodology (i.e. neutral loss, precursor ion, and product ion scanning modes) described previously and were determined to contain M6.
This article has not been copyedited and formatted. The final version may differ from this version. estimates since the span ratio was less than two, and this has direct consequences on the degree of confidence in presented CL/F and AUC values, which too are at best estimates.
Active renal secretion of 1 was observed as its unbound CL R was 3-fold greater than
GFR. An average brain-to-serum AUC 0-24 ratio of 28 suggests 1 has extensive brain penetration in rats, consistent with its physicochemical properties and it not being a multidrug resistance 1 P-glycoprotein substrate.
A schematic overview of the metabolism of 1 in Sprague-Dawley rats is presented in and rat hepatocytes (over 4 h). This was also true for an authentic standard of the regioisomeric lactam of 2, which produced M1 (minor) and M3 (major) when treated with aqueous base.
The most intriguing metabolic pathway for 1 was its conversion to N-carbamoyl glucuronide M6, which was isolated for its structural confirmation by NMR analysis;
NMR and MS spectra of N-carbamoyl glucuronides are well-characterized in the literature (Shaffer et al., 2005; Schaefer, 2006) . Additionally, the stability of Ncarbamoyl glucuronides in buffer (Thomas et al., 2008) , urine (Elvin et al., 1980; Straub et al., 1988) , plasma (Tremaine et al., 1989) and serum (Thomas et al., 2008) are also nicely documented. More interesting than purely the identification of M6 as an Ncarbamoyl glucuronide was its influence over the disposition of 1 (and total radioactivity) This article has not been copyedited and formatted. The final version may differ from this version. amounts (≥65%) of orally-dosed radioactivity were observed in bile with a concomitant drop in urinary and fecal radioactivity. These excretion patterns coupled with the doublehumped serum concentration-time curves suggested that 1 was likely undergoing direct EHC. However, metabolite profiling of biliary radioactivity provided a much different interpretation, in that the predominant (>95%) biliary radioactive component was M6, a metabolite not detected in any other biological matrix, and not 1 (<1%). Together, these data clearly pointed to the indirect EHC of 1 via M6.
To define this suspicion more definitively, intravenous studies were conducted with 1 in both intact and BDC Sprague-Dawley rats to determine empirically the extent of 1 undergoing indirect EHC via M6. When compared to the pharmacokinetics in intact rats, CL in BDC rats was higher (1.7-fold) and V ss was lower (1.6-fold), resulting in a correspondingly shorter (2.5-fold) t 1/2 . These results suggest that the disposition of 1 in rats involves EHC, with 56% of the intravenous dose of 1 undergoing recirculation, an amount consistent with that (68% of dose) of M6 observed in bile from rats orally dosed (rather than direct recycling of 1 via biliary excretion) is proposed as the principal underlying mechanism of EHC of 1 in Sprague-Dawley rats.
Based on the reported data, a molecular mechanism rationalizing the EHC of 1 is proposed in Figure 6 . Following oral dosing and absorption, 1 undergoes hepaticmediated metabolic conversion to M6, which itself undergoes biliary clearance. Bile excretion into the upper gastrointestinal tract exposes M6 to intestinal microflora rich in β-glucuronidase (Scheline, 1973; Parkinson, 2001) , the enzyme responsible for the quantitative conversion of M6 to 1 in vitro, resulting in glucuronide hydrolysis and spontaneous decarboxylation to 1, which is predominately reabsorbed and ultimately enters systemic circulation ( Figure 6A ). (Hypothetically, M6, which was converted directly to 1 by strong aqueous base (1 N NaOH, pH 14), may also be hydrolyzed nonenzymatically within the intestine (pH 6.8). However, this seems less likely as M6 was (±NADPH, 2 mg protein/mL, 10 μM 1) failed to metabolize 1, but they did convert 1 to M6 (ca. 15% conversion at 25 μM) when optimized for N-carbamoyl glucuronidation.
These results are supported by a recent dataset (Cerny et al., 2008) reporting that under similar conditions hepatic microsomes had a 25-fold greater relative rate than intestinal microsomes for the formation of an N-carbamoyl glucuronide of the structurally similar secondary alicyclic amine Lorcaserin.
It is worthy of note that two glucuronide metabolites were observed in rats: the predominant N-carbamoyl glucuronide (M6) and the minor N-O-glucuronide (M5).
Whereas M6 was only in bile, M5 was observed in bile (minimally), serum and urine.
This suggests that once formed hepatically M6 undergoes exclusive biliary clearance.
Alternatively, M5 does not solely undergo biliary clearance, rather it reaches systemic circulation and is ultimately excreted renally. This yet-defined selectivity may be due to a glucuronide-centric hepatic transporter, such as the organic ion transporter mrp2 (Klaassen and Watkins III, 1984; Keppler and Arias, 1997; Seitz et al., 1998; Xiong et al., 2000; Westley et al., 2006) , within the canalicular membrane that results in the preferential transport of M6 over M5 into bile. Conversely, it may be hypothesized that M5 undergoes preferential (versus M6) transport into blood, such as that mediated by mrp3 (Soroka et al., 2001; Villaneuva et al., 2008) . This mrp2 hypothesis is currently being investigated within our laboratory using either probenecid-treated wild-type rats or
Wistar TR -rats lacking mrp2 (Jansen et al., 1985; Xiong et al., 2000) .
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, not detected. a Intact animals (Group 1, N=3/gender). b Bile duct-cannulated animals (Group 2, N=2/gender). c % of dose. d Sum of dose recovered in bile, urine and feces from 0-48 h post-dose. In male bile ductcannulated rats, 17.7% and 9.0% of the dose was excreted in urine and feces, respectively. For female counterparts, 29.0% and 2.0% of the dose was recovered in urine and feces, respectively. e For each matrix, this value is calculated by dividing the sum of the metabolite profile by the total dose excreted and multiplying by 100. a Units are ng/mL and ng-eq./mL for 1 and total radioactivity, respectively.
b Units are ng•h/mL and ng-eq.
•h/mL for 1 and total radioactivity, respectively.
c Units are mL/min/kg.
d Calculated by Ae 0-168 /AUC 0-∞ and animal weight-normalized.
e Unbound plasma fraction was 0.60, GFR was assumed to be 1.31 mL/min (Davies and Morris, 1993) and animal weight-normalized.
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c Metabolites were quantified as one radioactive entity since they were resolved by mass spectrometry, but not by radiochromatography.
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